« Return to News | Drug Sponsors

Mylan expands in Ireland, creates 500 jobs

Wednesday, April 18, 2012 02:54 PM

Mylan, a generics and specialty pharmaceutical company based in Canonsburg, Penn., will expand its operations in Dublin and Galway, Ireland, by investing up to $100 million over the next five years.

The investment will fund expanded R&D and manufacturing capabilities within the company's respiratory, injectables and oral solids franchises. In addition, with support from the Irish Development Authority (IDA), Myland will add more than 500 new positions to its Ireland-based workforce by 2016.

"The expansion of Mylan's operations in Ireland is an extremely positive development for Ireland's life sciences sector,” said Barry O'Leary, CEO of IDA. “These projects meet with key objectives of IDA Ireland's strategy Horizon 2020 to create high quality life sciences jobs. I wish Mylan every success with this operation and on behalf of IDA Ireland look forward to continuing to work closely and support the company in the future.''

Mylan's operations in Ireland include Gerard Laboratories and Bioniche Pharma.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.